EUVIMEDEUVIMED entdecken
Crossref

A Real-World Pharmacovigilance Analysis of HER2 Inhibitor-Induced Cardiovascular Toxicity

Jianhui Yao, Chao Tao, Weiyi Chen, Ruixiao Li, Ke Wang, Jinlu Shang, Meiling Zhou

Oncology · 2026

DOI: 10.1159/000553521 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology, 2026. Verfasst von Jianhui Yao und 6 weiteren Autor:innen. Beteiligte Einrichtung: West China Hospital Sichuan University, Meishan Hospital, Meishan, China. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Cardiovascular Diseases, Protein Kinase Inhibitors, Antineoplastic Agents. Die Arbeit nennt 43 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

With the widespread use of human epidermal growth factor receptor 2 (HER2) inhibitors in cancer treatment, cardiovascular diseases induced by these agents have become a significant adverse event.

Methods

We retrieved reports of HER2 inhibitor-induced cardiovascular adverse events (CVAEs) from the FDA Adverse Event Reporting System(FAERS) database, covering the period from the first quarter of 2004 to the fourth quarter of 2024. Disproportionality analyses were conducted using reporting odds ratios and proportional reporting ratios. The signals of HER2 inhibitor-related CVAEs were evaluated at both the standardized MedDRA query and preferred term levels.

Results

A total of 12,698 reports associated with CVAEs were identified, with HER2 inhibitors listed as the primary suspected drug, involving 12,398 patients. Most cases were observed in individuals aged 45 years and older, with a notably higher proportion in women. The time to onset of HER2 inhibitor-induced CVAEs showed certain variability. Trastuzumab exhibited higher cardiovascular toxicity compared with other HER2 inhibitors. In general, monoclonal antibodies demonstrated greater cardiovascular toxicity, whereas antibody-drug conjugates and HER2-tyrosine kinase inhibitors displayed comparable and lower effects.

Conclusion

This pharmacovigilance analysis reveals a strong association between HER2 inhibitors and CVAEs, providing valuable insights for their prevention and clinical management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Erb-b2 Receptor Tyrosine KinasesCardiovascular DiseasesProtein Kinase InhibitorsAntineoplastic AgentsHumansPharmacovigilanceFemaleMiddle AgedAgedMaleAdverse Drug Reaction Reporting SystemsAdultTrastuzumabAged, 80 and over

Stichwörter der Autor:innen

Antibody-drug conjugatesCardiovascular toxicityFAERSHER2 inhibitorsMonoclonal antibodiesSmall molecule tyrosine kinase inhibitors

Substanzen

Erb-b2 Receptor Tyrosine KinasesERBB2 protein, humanProtein Kinase InhibitorsTrastuzumabAntineoplastic Agents

Autor:innen und Institutionen

  • West China Hospital Sichuan University, Meishan Hospital, Meishan, China.
  • Department of Cardiology, Meishan People's Hospital, Meishan, China.
  • Department of Pharmacy, The Affiliated Hospital, Southwest Medical University, Luzhou, China.
  • Department of Clinical Pharmacy, School of Pharmacy, Southwest Medical University, Luzhou, China.
  • Department of Pharmacy, West China Hospital Sichuan University Jintang Hospital · Jintang First People's Hospital, Chengdu, China, 15883056860@163.com.
  • Department of Pharmacy, The Affiliated Hospital, Southwest Medical University, Luzhou, China, meilzhou@swmu.edu.cn.

Zitieren

APA

Yao, J., Tao, C., Chen, W., Li, R., Wang, K., Shang, J., & Zhou, M. (2026). A Real-World Pharmacovigilance Analysis of HER2 Inhibitor-Induced Cardiovascular Toxicity. Oncology. https://doi.org/10.1159/000553521

Vancouver

Yao J, Tao C, Chen W, Li R, Wang K, Shang J, et al. A Real-World Pharmacovigilance Analysis of HER2 Inhibitor-Induced Cardiovascular Toxicity. Oncology. 2026. doi:10.1159/000553521

BibTeX
@article{Yao2026,
  author = {Yao, Jianhui and Tao, Chao and Chen, Weiyi and Li, Ruixiao and Wang, Ke and Shang, Jinlu and Zhou, Meiling},
  title = {A Real-World Pharmacovigilance Analysis of HER2 Inhibitor-Induced Cardiovascular Toxicity},
  journal = {Oncology},
  year = {2026},
  doi = {10.1159/000553521}
}
Kostenlos starten →